CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $111,656
- in 2 filings
Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-02-20 | SCHMIDT ERIC THOMAS Chief Financial Officer | Other disposition | −237,155 | $25.30 | $6.0M | 1,227,595 |
| 2019-11-19 | Kazam Joshua A Director | Other acquisition | +8,217 | 1,453,703 | ||
| 2019-11-19 | Chang David D President and CEO | Other acquisition | +9,402 | 1,182,508 | ||
| 2019-11-19 | Chang David D President and CEO | Other acquisition | +9,391 | 2,224,745 | ||
| 2019-11-11 | Kazam Joshua A Director | Gift | −446,623 | 1,007,080 | ||
| 2019-10-25 | Chang David D President and CEO | Other acquisition | +9,402 | 1,173,106 | ||
| 2019-10-25 | Chang David D President and CEO | Other acquisition | +9,391 | 2,215,354 | ||
| 2019-10-25 | Kazam Joshua A Director | Other acquisition | +8,217 | 1,445,486 | ||
| 2019-09-23 | Chang David D President and CEO | Other acquisition | +9,402 | 1,163,704 | ||
| 2019-09-23 | Chang David D President and CEO | Other acquisition | +9,391 | 2,205,963 | ||
| 2019-09-23 | Kazam Joshua A Director | Other acquisition | +8,217 | 1,437,269 | ||
| 2019-09-18 | MOORE ALISON Chief Technical Officer | Option exercise | +21,067 | $2.27 | $48K | 87,134 |
| 2019-09-18 | MOORE ALISON Chief Technical Officer | Sale | −21,067 | $32.13 | $677K | 66,067 |
| 2019-09-18 | MOORE ALISON Chief Technical Officer | Option exercise · Stock Option (Right to Buy) | −21,067 | 718,202 | ||
| 2019-09-17 | MOORE ALISON Chief Technical Officer | Option exercise | +22,503 | $2.27 | $51K | 88,570 |
| 2019-09-17 | MOORE ALISON Chief Technical Officer | Sale | −22,503 | $32.11 | $723K | 66,067 |
| 2019-09-17 | MOORE ALISON Chief Technical Officer | Option exercise · Stock Option (Right to Buy) | −22,503 | 739,269 | ||
| 2019-09-16 | MOORE ALISON Chief Technical Officer | Option exercise | +5,257 | $2.27 | $12K | 71,324 |
| 2019-09-16 | MOORE ALISON Chief Technical Officer | Sale | −5,257 | $32.00 | $168K | 66,067 |
| 2019-09-16 | MOORE ALISON Chief Technical Officer | Option exercise · Stock Option (Right to Buy) | −5,257 | 761,772 |
Page 19 of 23 · 451 trades